Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Cutaneous xanthomas

Karolyn Wanat, MD
Megan H Noe, MD, MPH
Section Editors
Jeffrey Callen, MD, FACP, FAAD
Mason W Freeman, MD
Deputy Editor
Abena O Ofori, MD


Xanthomas are localized lipid deposits within organs that may manifest as papules, plaques, or nodules in skin. The clinical variants of cutaneous xanthomas include:

Eruptive xanthomas (picture 1A-C)

Tuberous xanthomas (picture 2A-C)

Tendinous xanthomas (picture 3)

Plane xanthomas (including xanthelasma) (picture 4A-C)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Nov 10, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Zak A, Zeman M, Slaby A, Vecka M. Xanthomas: clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2014; 158:181.
  2. Love JR, Dubin HV. Xanthomas and lipoproteins. Cutis 1978; 21:801.
  3. Cruz PD Jr, East C, Bergstresser PR. Dermal, subcutaneous, and tendon xanthomas: diagnostic markers for specific lipoprotein disorders. J Am Acad Dermatol 1988; 19:95.
  4. Parker F. Normocholesterolemic xanthomatosis. Arch Dermatol 1986; 122:1253.
  5. Parker F, Bagdade JD, Odland GF, Bierman EL. Evidence for the chylomicron origin of lipids accumulating in diabetic eruptive xanthomas: a correlative lipid biochemical, histochemical, and electron microscopic study. J Clin Invest 1970; 49:2172.
  6. Wilson JD. Studies on the origin of the lipid components of xanthomata. Circ Res 1963; 12:472.
  7. Hu CH, Ellefson RD, Winkelmann RK. Lipid synthesis in cutaneous xanthoma. J Invest Dermatol 1982; 79:80.
  8. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67:968.
  9. Smellie WS. Hypertriglyceridaemia in diabetes. BMJ 2006; 333:1257.
  10. Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis 1994; 23:331.
  11. Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39:169.
  12. O'Brien T, Dinneen SF, O'Brien PC, Palumbo PJ. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993; 68:860.
  13. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325:1196.
  14. Crook D, Cust MP, Gangar KF, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992; 166:950.
  15. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122:133.
  16. Hilbrands LB, Demacker PN, Hoitsma AJ, et al. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 1995; 5:2073.
  17. Klör HU, Weizel A, Augustin M, et al. The impact of oral vitamin A derivatives on lipid metabolism - What recommendations can be derived for dealing with this issue in the daily dermatological practice? J Dtsch Dermatol Ges 2011; 9:600.
  18. Sayin I, Ayli M, Oğuz AK, Seval GC. Xanthelasma palpebrarum: a new side effect of nilotinib. BMJ Case Rep 2016; 2016.
  19. Szalat R, Arnulf B, Karlin L, et al. Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy. Blood 2011; 118:3777.
  20. Hegde U, Doddawad VG, Sreeshyla H, Patil R. Verruciform xanthoma: A view on the concepts of its etiopathogenesis. J Oral Maxillofac Pathol 2013; 17:392.
  21. Cutaneous infiltrates - Non-lymphoid. In: Weedon's Skin Pathology, 4th ed, Patterson JW, Hosler GA, Weedon D (Eds), Churchill Livingstone Elsevier, Philadelphia 2015. p.1129.
  22. Ravić-Nikolić A, Mladenović V, Mitrović S, et al. Generalized eruptive xanthomas associated with diabetic dyslipidemia. Eur J Dermatol 2014; 24:394.
  23. Solak B, Kara RO, Acikgoz SB, Kosem M. First and only symptom of undiagnosed diabetes mellitus: eruptive xanthoma. BMJ Case Rep 2015; 2015.
  24. Bounouar M, Mernissi F. [Eruptive xanthomas announcing severe acute pancreatitis]. Pan Afr Med J 2014; 17:225.
  25. Moghadasian MH. Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds. Clin Invest Med 2004; 27:42.
  26. Bhattacharyya AK, Connor WE. Beta-sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters. J Clin Invest 1974; 53:1033.
  27. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012; 223:262.
  28. Baila-Rueda L, Mateo-Gallego R, Lamiquiz-Moneo I, et al. Severe hypercholesterolemia and phytosterolemia with extensive xanthomas in primary biliary cirrhosis: role of biliary excretion on sterol homeostasis. J Clin Lipidol 2014; 8:520.
  29. Macías-Rodríguez RU, Torre-Delgadillo A. Xanthelasmas and xanthomatas striatum palmare in primary biliary cirrhosis. Ann Hepatol 2006; 5:49.
  30. Weston CF, Burton JL. Xanthomas in the Watson-Alagille syndrome. J Am Acad Dermatol 1987; 16:1117.
  31. Bergman R. The pathogenesis and clinical significance of xanthelasma palpebrarum. J Am Acad Dermatol 1994; 30:236.
  32. Ozdöl S, Sahin S, Tokgözoğlu L. Xanthelasma palpebrarum and its relation to atherosclerotic risk factors and lipoprotein (a). Int J Dermatol 2008; 47:785.
  33. Dwivedi S, Aggarwal A, Singh S, Sharma V. Familial xanthelasma with dyslipidemia: just another family trait? N Am J Med Sci 2012; 4:238.
  34. Lynch MC, Wood L, Anderson BE, Clarke LE. JAAD Grand Rounds. Asymptomatic dermal plaques. J Am Acad Dermatol 2015; 72:922.
  35. Marcoval J, Moreno A, Bordas X, et al. Diffuse plane xanthoma: clinicopathologic study of 8 cases. J Am Acad Dermatol 1998; 39:439.
  36. Blankenship DW, Zech L, Mirzabeigi M, Venna S. Verruciform xanthoma of the upper-extremity in the absence of chronic skin disease or syndrome: a case report and review of the literature. J Cutan Pathol 2013; 40:745.
  37. Curto-Barredo L, Segura S, Barranco C, et al. Verruciform xanthoma developing in recessive dystrophic epidermolysis bullosa: A sheep in wolf's clothing. Am J Dermatopathol 2014; 36:506.
  38. Xu XL, Huang LM, Wang Q, Sun JF. Multiple verruciform xanthomas in the setting of congenital hemidysplasia with ichthyosiform erythroderma and limb defects syndrome. Pediatr Dermatol 2015; 32:135.
  39. Chyu J, Medenica M, Whitney DH. Verruciform xanthoma of the lower extremity--report of a case and review of literature. J Am Acad Dermatol 1987; 17:695.
  40. Huguet P, Toran N, Tarragona J. Cutaneous verruciform xanthoma arising on a congenital lymphoedematous leg. Histopathology 1995; 26:277.
  41. Romaní J, Luelmo J, Sáez A, et al. Localized xanthomas associated with primary lymphedema. Pediatr Dermatol 2012; 29:113.
  42. Mannes KD, Dekle CL, Requena L, Sangueza OP. Verruciform xanthoma associated with squamous cell carcinoma. Am J Dermatopathol 1999; 21:66.
  43. Shahrabi Farahani S, Treister NS, Khan Z, Woo SB. Oral verruciform xanthoma associated with chronic graft-versus-host disease: a report of five cases and a review of the literature. Head Neck Pathol 2011; 5:193.
  44. Polonowita AD, Firth NA, Rich AM. Verruciform xanthoma and concomitant lichen planus of the oral mucosa. A report of three cases. Int J Oral Maxillofac Surg 1999; 28:62.
  45. Miyamoto Y, Nagayama M, Hayashi Y. Verruciform xanthoma occurring within oral lichen planus. J Oral Pathol Med 1996; 25:188.
  46. Harris L, Staines K, Pring M. Oral verruciform xanthoma. BMJ Case Rep 2015; 2015.
  47. Gong HZ, Zheng HY, Li J. Xanthoma disseminatum. Lancet 2017.
  48. Yamamoto A, Matsuzawa Y, Yokoyama S, et al. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol 1986; 57:29H.
  49. Fujita M, Shirai K. A comparative study of the therapeutic effect of probucol and pravastatin on xanthelasma. J Dermatol 1996; 23:598.
  50. Inazu A, Koizumi J, Kajinami K, et al. Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. Atherosclerosis 1999; 145:405.
  51. Lee HY, Jin US, Minn KW, Park YO. Outcomes of surgical management of xanthelasma palpebrarum. Arch Plast Surg 2013; 40:380.
  52. Mourad B, Elgarhy LH, Ellakkawy HA, Elmahdy N. Assessment of efficacy and tolerability of different concentrations of trichloroacetic acid vs. carbon dioxide laser in treatment of xanthelasma palpebrarum. J Cosmet Dermatol 2015; 14:209.
  53. Esmat SM, Elramly AZ, Abdel Halim DM, et al. Fractional CO2 laser is an effective therapeutic modality for xanthelasma palpebrarum: a randomized clinical trial. Dermatol Surg 2014; 40:1349.
  54. Güngör S, Canat D, Gökdemir G. Erbium: YAG laser ablation versus 70% trichloroacetıc acid application in the treatment of xanthelasma palpebrarum. J Dermatolog Treat 2014; 25:290.
  55. Labandeira J, Vázquez-Osorio I, Figueroa-Silva O, et al. Tolerability and effectiveness of liquid nitrogen spray cryotherapy with very short freeze times in the treatment of xanthelasma palpebrarum. Dermatol Ther 2015; 28:346.
  56. Heng JK, Chua SH, Goh CL, et al. Treatment of xanthelasma palpebrarum with a 1064-nm, Q-switched Nd:YAG laser. J Am Acad Dermatol 2017; 77:728.
  57. Lorenz S, Hohenleutner S, Hohenleutner U, Landthaler M. Treatment of diffuse plane xanthoma of the face with the Erbium:YAG laser. Arch Dermatol 2001; 137:1413.
  58. Guo Y, Dang Y, Toyohara JP, Geng S. Successful treatment of verruciform xanthoma with imiquimod. J Am Acad Dermatol 2013; 69:e184.
  59. Connolly SB, Lewis EJ, Lindholm JS, et al. Management of cutaneous verruciform xanthoma. J Am Acad Dermatol 2000; 42:343.
  60. Mohsin SK, Lee MW, Amin MB, et al. Cutaneous verruciform xanthoma: a report of five cases investigating the etiology and nature of xanthomatous cells. Am J Surg Pathol 1998; 22:479.
  61. Joo J, Fung MA, Jagdeo J. Successful treatment of scrotal verruciform xanthoma with shave debulking and fractionated carbon dioxide laser therapy. Dermatol Surg 2014; 40:214.
  62. Esmat S, Abdel-Halim MR, Fawzy MM, et al. Are normolipidaemic patients with xanthelasma prone to atherosclerosis? Clin Exp Dermatol 2015; 40:373.